Author:
Herting Cameron J.,Karpovsky Isaac,Lesinski Gregory B.
Funder
national institutes of health
Publisher
Springer Science and Business Media LLC
Reference169 articles.
1. Siegel, R. L., et al. (2021). Cancer statistics, 2021. CA: A Cancer Journal for Clinicians, 71(1), 7–33.
2. Deshwar, A.B., et al. (2018). Diagnostic intervals and pancreatic ductal adenocarcinoma (PDAC) resectability: A single-center retrospective analysis. Ann Pancreat Cancer. 1.
3. Ansari, D., Gustafsson, A., & Andersson, R. (2015). Update on the management of pancreatic cancer: Surgery is not enough. World Journal of Gastroenterology, 21(11), 3157–3165.
4. Bekkali, N. L. H., & Oppong, K. W. (2017). Pancreatic ductal adenocarcinoma epidemiology and risk assessment: Could we prevent? Possibility for an early diagnosis. Endosc Ultrasound, 6(Suppl 3), S58–S61.
5. Conroy, T., et al. (2011). FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. New England Journal of Medicine, 364(19), 1817–1825.
Cited by
38 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献